Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pentoxifylline in Patients With Ulcerative Colitis
Sponsor: Ihab Elsayed Hassan
Summary
Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.
Official title: Clinical Study Evaluating Safety and Efficacy of Pentoxifylline in Patients With Ulcerative Colitis
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-01-20
Completion Date
2027-02-20
Last Updated
2026-01-16
Healthy Volunteers
No
Conditions
Interventions
Mesalamine
Mesalamine is the standard first line treatment of ulcerative colitis
Pentoxifylline
Pentoxifylline (PTX), a methylxanthine derivative and non-selective phosphodiesterase inhibitor, has been extensively studied for its anti-inflammatory and immunomodulatory actions. It inhibits TNF-α production at the transcriptional level and downregulates several inflammatory cytokines, including IL-1β, IL-6, and interferon-γ
Locations (1)
Fayoum University
Al Fayyum, Egypt